Research ExplorerPublicationsPreclinical models for neuroblastoma: establishing a baselin...

Preclinical models for neuroblastoma: establishing a baseline for treatment.

Standard

Preclinical models for neuroblastoma: establishing a baseline for treatment. / Teitz, Tal; Stanke, Jennifer J; Federico, Sara; Bradley, Cori L; Brennan, Rachel; Zhang, Jiakun; Johnson, Melissa D; Sedlacik, Jan; Inoue, Madoka; Zhang, Ziwei M; Frase, Sharon; Rehg, Jerold E; Hillenbrand, Claudia M; Finkelstein, David; Calabrese, Christopher; Dyer, Michael A; Lahti, Jill M.

In: PLOS ONE, Vol. 6, No. 4, 4, 2011, p. 19133.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Teitz, T, Stanke, JJ, Federico, S, Bradley, CL, Brennan, R, Zhang, J, Johnson, MD, Sedlacik, J, Inoue, M, Zhang, ZM, Frase, S, Rehg, JE, Hillenbrand, CM, Finkelstein, D, Calabrese, C, Dyer, MA & Lahti, JM 2011, 'Preclinical models for neuroblastoma: establishing a baseline for treatment.', PLOS ONE, vol. 6, no. 4, 4, pp. 19133. <http://www.ncbi.nlm.nih.gov/pubmed/21559450?dopt=Citation>

APA

Teitz, T., Stanke, J. J., Federico, S., Bradley, C. L., Brennan, R., Zhang, J., Johnson, M. D., Sedlacik, J., Inoue, M., Zhang, Z. M., Frase, S., Rehg, J. E., Hillenbrand, C. M., Finkelstein, D., Calabrese, C., Dyer, M. A., & Lahti, J. M. (2011). Preclinical models for neuroblastoma: establishing a baseline for treatment. PLOS ONE, 6(4), 19133. [4]. http://www.ncbi.nlm.nih.gov/pubmed/21559450?dopt=Citation

Vancouver

Teitz T, Stanke JJ, Federico S, Bradley CL, Brennan R, Zhang J et al. Preclinical models for neuroblastoma: establishing a baseline for treatment. PLOS ONE. 2011;6(4):19133. 4.

Bibtex

@article{d5ed95d009e54975a2ecf892138a5274,
title = "Preclinical models for neuroblastoma: establishing a baseline for treatment.",
abstract = "Preclinical models of pediatric cancers are essential for testing new chemotherapeutic combinations for clinical trials. The most widely used genetic model for preclinical testing of neuroblastoma is the TH-MYCN mouse. This neuroblastoma-prone mouse recapitulates many of the features of human neuroblastoma. Limitations of this model include the low frequency of bone marrow metastasis, the lack of information on whether the gene expression patterns in this system parallels human neuroblastomas, the relatively slow rate of tumor formation and variability in tumor penetrance on different genetic backgrounds. As an alternative, preclinical studies are frequently performed using human cell lines xenografted into immunocompromised mice, either as flank implant or orthtotopically. Drawbacks of this system include the use of cell lines that have been in culture for years, the inappropriate microenvironment of the flank or difficult, time consuming surgery for orthotopic transplants and the absence of an intact immune system.",
keywords = "Animals, Humans, Disease Models, Animal, Mice, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Transgenic, Genes, myc, Immunohistochemistry/methods, Neoplasm Transplantation, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Drug Screening Assays, Antitumor, Nervous System Neoplasms/genetics/*pathology, Neuroblastoma/genetics/*pathology, Animals, Humans, Disease Models, Animal, Mice, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Transgenic, Genes, myc, Immunohistochemistry/methods, Neoplasm Transplantation, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Drug Screening Assays, Antitumor, Nervous System Neoplasms/genetics/*pathology, Neuroblastoma/genetics/*pathology",
author = "Tal Teitz and Stanke, {Jennifer J} and Sara Federico and Bradley, {Cori L} and Rachel Brennan and Jiakun Zhang and Johnson, {Melissa D} and Jan Sedlacik and Madoka Inoue and Zhang, {Ziwei M} and Sharon Frase and Rehg, {Jerold E} and Hillenbrand, {Claudia M} and David Finkelstein and Christopher Calabrese and Dyer, {Michael A} and Lahti, {Jill M}",
year = "2011",
language = "English",
volume = "6",
pages = "19133",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

RIS

TY - JOUR

T1 - Preclinical models for neuroblastoma: establishing a baseline for treatment.

AU - Teitz, Tal

AU - Stanke, Jennifer J

AU - Federico, Sara

AU - Bradley, Cori L

AU - Brennan, Rachel

AU - Zhang, Jiakun

AU - Johnson, Melissa D

AU - Sedlacik, Jan

AU - Inoue, Madoka

AU - Zhang, Ziwei M

AU - Frase, Sharon

AU - Rehg, Jerold E

AU - Hillenbrand, Claudia M

AU - Finkelstein, David

AU - Calabrese, Christopher

AU - Dyer, Michael A

AU - Lahti, Jill M

PY - 2011

Y1 - 2011

N2 - Preclinical models of pediatric cancers are essential for testing new chemotherapeutic combinations for clinical trials. The most widely used genetic model for preclinical testing of neuroblastoma is the TH-MYCN mouse. This neuroblastoma-prone mouse recapitulates many of the features of human neuroblastoma. Limitations of this model include the low frequency of bone marrow metastasis, the lack of information on whether the gene expression patterns in this system parallels human neuroblastomas, the relatively slow rate of tumor formation and variability in tumor penetrance on different genetic backgrounds. As an alternative, preclinical studies are frequently performed using human cell lines xenografted into immunocompromised mice, either as flank implant or orthtotopically. Drawbacks of this system include the use of cell lines that have been in culture for years, the inappropriate microenvironment of the flank or difficult, time consuming surgery for orthotopic transplants and the absence of an intact immune system.

AB - Preclinical models of pediatric cancers are essential for testing new chemotherapeutic combinations for clinical trials. The most widely used genetic model for preclinical testing of neuroblastoma is the TH-MYCN mouse. This neuroblastoma-prone mouse recapitulates many of the features of human neuroblastoma. Limitations of this model include the low frequency of bone marrow metastasis, the lack of information on whether the gene expression patterns in this system parallels human neuroblastomas, the relatively slow rate of tumor formation and variability in tumor penetrance on different genetic backgrounds. As an alternative, preclinical studies are frequently performed using human cell lines xenografted into immunocompromised mice, either as flank implant or orthtotopically. Drawbacks of this system include the use of cell lines that have been in culture for years, the inappropriate microenvironment of the flank or difficult, time consuming surgery for orthotopic transplants and the absence of an intact immune system.

KW - Animals

KW - Humans

KW - Disease Models, Animal

KW - Mice

KW - Gene Expression Regulation, Neoplastic

KW - Oligonucleotide Array Sequence Analysis

KW - Gene Expression Profiling

KW - Mice, Transgenic

KW - Genes, myc

KW - Immunohistochemistry/methods

KW - Neoplasm Transplantation

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Drug Screening Assays, Antitumor

KW - Nervous System Neoplasms/genetics/pathology

KW - Neuroblastoma/genetics/pathology

KW - Animals

KW - Humans

KW - Disease Models, Animal

KW - Mice

KW - Gene Expression Regulation, Neoplastic

KW - Oligonucleotide Array Sequence Analysis

KW - Gene Expression Profiling

KW - Mice, Transgenic

KW - Genes, myc

KW - Immunohistochemistry/methods

KW - Neoplasm Transplantation

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Drug Screening Assays, Antitumor

KW - Nervous System Neoplasms/genetics/pathology

KW - Neuroblastoma/genetics/pathology

M3 - SCORING: Journal article

VL - 6

SP - 19133

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 4

M1 - 4

ER -